OTLK
Outlook Therapeutics, Inc.
Biotechnology
Market Cap$14M
5Y Perf.-98.9%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
OTLK vs RCKT
Revenue, margins, valuation, and 5-year total return — side by side.
RCKT
Rocket Pharmaceuticals, Inc.
Biotechnology
Market Cap$398M
5Y Perf.-80.5%
OTLK vs RCKT — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | OTLK | RCKT |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $14M | $398M |
| Revenue (TTM) | $206K | $0.00 |
| Net Income (TTM) | $-103M | $-223M |
| Gross Margin | -5.9% | — |
| Operating Margin | -286.8% | — |
| Total Debt | $247.70B | $25M |
| Cash & Equiv. | $8.08T | $78M |
OTLK vs RCKT — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
OTLK
RCKT
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Outlook Therapeutic… (OTLK) | 100 | 1.1 | -98.9% |
| Rocket Pharmaceutic… (RCKT) | 100 | 19.5 | -80.5% |
Price return only. Dividends and distributions are not included.
Quick Verdict: OTLK vs RCKT
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: OTLK and RCKT are tied at the top with 2 categories each — the right choice depends on your priorities. Rocket Pharmaceuticals, Inc. is the stronger pick specifically for capital preservation and lower volatility and recent price momentum and sentiment. As sector peers, any of these can serve as alternatives in the same allocation.
OTLK
Outlook Therapeutics, Inc.
The Growth Play
OTLK has the current edge in this matchup, primarily because of its strength in growth exposure.
- Rev growth 20.8%, EPS growth 55.9%
- 20.8% revenue growth vs RCKT's 10.5%
- -0.0% ROA vs RCKT's -67.5%
Best for: growth exposure
RCKT
Rocket Pharmaceuticals, Inc.
The Income Pick
RCKT is the clearest fit if your priority is income & stability and long-term compounding.
- beta 1.31
- -91.3% 10Y total return vs OTLK's -100.0%
- Lower volatility, beta 1.31, Low D/E 9.0%, current ratio 6.38x
Best for: income & stability and long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | OTLK | 20.8% revenue growth vs RCKT's 10.5% |
| Stability / Safety | RCKT | Beta 1.31 vs OTLK's 1.54 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | RCKT | -45.2% vs OTLK's -84.7% |
| Efficiency (ROA) | OTLK | -0.0% ROA vs RCKT's -67.5% |
OTLK vs RCKT — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLRCKTLAGGINGOTLK
OTLKOutlook Therapeutics,…
1leads
RCKTRocket Pharmaceutical…
4leads
6 Total Categories
CATEGORYLEADERvs OTLKMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
RCKT1/1
Valuation MetricsMultiples, price ratios, and targets
RCKT1/1
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
OTLK3/4
Total Returns1Y, 3Y, 5Y total returns with dividends
RCKT6/6
Risk & VolatilityBeta, volatility, and downside exposure
RCKT2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
RCKT leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
OTLK and RCKT operate at a comparable scale, with $205,535 and $0 in trailing revenue.
| Metric | OTLKOutlook Therapeut… | RCKTRocket Pharmaceut… |
|---|---|---|
| RevenueTrailing 12 months | $205,535 | $0 |
| EBITDAEarnings before interest/tax | -$59M | -$232M |
| Net IncomeAfter-tax profit | -$103M | -$223M |
| Free Cash FlowCash after capex | -$14.94T | -$190M |
| Gross MarginGross profit ÷ Revenue | -5.9% | — |
| Operating MarginEBIT ÷ Revenue | -286.8% | — |
| Net MarginNet income ÷ Revenue | -500.5% | — |
| FCF MarginFCF ÷ Revenue | -999999.0% | — |
| Rev. Growth (YoY)Latest quarter vs prior year | — | — |
| EPS Growth (YoY)Latest quarter vs prior year | -152.8% | +38.7% |
RCKT leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
RCKT leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
| Metric | OTLKOutlook Therapeut… | RCKTRocket Pharmaceut… |
|---|---|---|
| Market CapShares × price | $14M | $398M |
| Enterprise ValueMkt cap + debt − cash | -$7.84T | $345M |
| Trailing P/EPrice ÷ TTM EPS | -0.12x | -1.83x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | 9.85x | — |
| Price / BookPrice ÷ Book value/share | — | 1.47x |
| Price / FCFMarket cap ÷ FCF | — | — |
RCKT leads this category, winning 1 of 1 comparable metric.
Profitability & Efficiency
OTLK leads this category, winning 3 of 4 comparable metrics.
Profitability & Efficiency
On the Piotroski fundamental quality scale (0–9), OTLK scores 4/9 vs RCKT's 1/9, reflecting mixed financial health.
| Metric | OTLKOutlook Therapeut… | RCKTRocket Pharmaceut… |
|---|---|---|
| ROE (TTM)Return on equity | — | -80.5% |
| ROA (TTM)Return on assets | -0.0% | -67.5% |
| ROICReturn on invested capital | — | -63.2% |
| ROCEReturn on capital employed | — | -58.9% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 1 |
| Debt / EquityFinancial leverage | — | 0.09x |
| Net DebtTotal debt minus cash | -$7.84T | -$53M |
| Cash & Equiv.Liquid assets | $8.08T | $78M |
| Total DebtShort + long-term debt | $247.7B | $25M |
| Interest CoverageEBIT ÷ Interest expense | -182.41x | — |
OTLK leads this category, winning 3 of 4 comparable metrics.
Total Returns (Dividends Reinvested)
RCKT leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in RCKT five years ago would be worth $838 today (with dividends reinvested), compared to $50 for OTLK. Over the past 12 months, RCKT leads with a -45.2% total return vs OTLK's -84.7%. The 3-year compound annual growth rate (CAGR) favors RCKT at -44.4% vs OTLK's -78.9% — a key indicator of consistent wealth creation.
| Metric | OTLKOutlook Therapeut… | RCKTRocket Pharmaceut… |
|---|---|---|
| YTD ReturnYear-to-date | -67.3% | +6.1% |
| 1-Year ReturnPast 12 months | -84.7% | -45.2% |
| 3-Year ReturnCumulative with dividends | -99.1% | -82.8% |
| 5-Year ReturnCumulative with dividends | -99.5% | -91.6% |
| 10-Year ReturnCumulative with dividends | -100.0% | -91.3% |
| CAGR (3Y)Annualised 3-year return | -78.9% | -44.4% |
RCKT leads this category, winning 6 of 6 comparable metrics.
Risk & Volatility
RCKT leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
RCKT is the less volatile stock with a 1.31 beta — it tends to amplify market swings less than OTLK's 1.54 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. RCKT currently trades 49.7% from its 52-week high vs OTLK's 6.4% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | OTLKOutlook Therapeut… | RCKTRocket Pharmaceut… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.54x | 1.31x |
| 52-Week HighHighest price in past year | $3.39 | $7.39 |
| 52-Week LowLowest price in past year | $0.16 | $2.19 |
| % of 52W HighCurrent price vs 52-week peak | +6.4% | +49.7% |
| RSI (14)Momentum oscillator 0–100 | 40.7 | 54.4 |
| Avg Volume (50D)Average daily shares traded | 4.0M | 3.5M |
RCKT leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
| Metric | OTLKOutlook Therapeut… | RCKTRocket Pharmaceut… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy |
| Price TargetConsensus 12-month target | — | $5.00 |
| # AnalystsCovering analysts | — | 19 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | 2 | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
RCKT leads in 4 of 6 categories (Income & Cash Flow, Valuation Metrics). OTLK leads in 1 (Profitability & Efficiency).
Best OverallRocket Pharmaceuticals, Inc. (RCKT)Leads 4 of 6 categories
Loading custom metrics...
OTLK vs RCKT: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is OTLK or RCKT a better buy right now?
Analysts rate Rocket Pharmaceuticals, Inc.
(RCKT) a "Buy" — based on 19 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — OTLK or RCKT?
Over the past 5 years, Rocket Pharmaceuticals, Inc.
(RCKT) delivered a total return of -91. 6%, compared to -99. 5% for Outlook Therapeutics, Inc. (OTLK). Over 10 years, the gap is even starker: RCKT returned -91. 3% versus OTLK's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — OTLK or RCKT?
By beta (market sensitivity over 5 years), Rocket Pharmaceuticals, Inc.
(RCKT) is the lower-risk stock at 1. 31β versus Outlook Therapeutics, Inc. 's 1. 54β — meaning OTLK is approximately 18% more volatile than RCKT relative to the S&P 500.
04Which is growing faster — OTLK or RCKT?
On earnings-per-share growth, the picture is similar: Outlook Therapeutics, Inc.
grew EPS 55. 9% year-over-year, compared to 26. 4% for Rocket Pharmaceuticals, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — OTLK or RCKT?
Rocket Pharmaceuticals, Inc.
(RCKT) is the more profitable company, earning 0. 0% net margin versus -44. 2% for Outlook Therapeutics, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: RCKT leads at 0. 0% versus -47. 4% for OTLK. At the gross margin level — before operating expenses — OTLK leads at 46. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — OTLK or RCKT?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is OTLK or RCKT better for a retirement portfolio?
For long-horizon retirement investors, Rocket Pharmaceuticals, Inc.
(RCKT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding. Outlook Therapeutics, Inc. (OTLK) carries a higher beta of 1. 54 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (RCKT: -91. 3%, OTLK: -100. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between OTLK and RCKT?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.